Novartis in $1bn cardiovascular deal with Ionis and Akcea

20-02-2017

Novartis in $1bn cardiovascular deal with Ionis and Akcea

Choreograph / iStockphoto.com

Novartis has finalised its agreement with biopharmaceutical company Ionis Pharmaceuticals and its wholly-owned subsidiary Akcea Therapeutics to develop and commercialise therapies for cardiovascular disorders.


Novartis, Ionis Pharmaceuticals, Akcea Therapeutics, cardiovascular disorders, agreement,

LSIPR